Company Description
NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases.
To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.
With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens.
Through our 20+ year history of research and development, we have developed Ii-Key vaccines that target the immune system against TAAs and infectious disease pathogens, including our lead product candidate, AE37 (Ii-Key-HER-2/neu) that is in Phase 2 clinical trials for HER-2 associated cancers, including breast, pancreatic, and bladder cancer.
Our other oncology product is Ii-Key-GP100 for melanoma that has been tested in a comprehensive pre-clinical program and is Phase I ready.
In addition to our work in immune-oncology, we have utilized the Ii-Key technology to rapidly develop vaccines against emerging pandemic threats.
| Country | United States |
| Founded | 1993 |
| Industry | Pharmaceutical Preparations |
| Sector | Biotechnology |
| Employees | 6 |
| CEO | Joseph Moscato |
Contact Details
Address: 10102 USA Today Way Miramar, FL 33025 United States | |
| Phone | (416) 364-2551 |
| Website | nugenerexio.com |
Stock Details
| Ticker Symbol | NGIO |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001804585 |
| Employer ID | 04-3208418 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 24, 2023 | REVOKED | Filing |
| Apr 7, 2023 | 8-K | Current Report |
| Nov 1, 2021 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Jul 23, 2021 | 8-K | Current Report |
| Jun 14, 2021 | 10-Q | Quarterly Report |
| May 24, 2021 | DEFR14C | Filing |
| May 21, 2021 | DEF 14C | Filing |
| May 20, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 19, 2021 | PRE 14C | Filing |
| May 19, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |